Diabetic Nephropathy Biomarkers and Mechanisms

Diabetic nephropathy arises from sustained hyperglycaemia and hypertension that induce structural and functional alterations across the glomerular and tubulointerstitial compartments of the kidney. Early changes include glomerular hyperfiltration, endothelial dysfunction and loss of permselectivity, manifesting clinically as microalbuminuria. Progressive injury to proximal tubule epithelial cells amplifies proteinuria and accelerates decline in glomerular filtration rate. Key pathogenic mechanisms comprise oxidative stress, advanced glycation end-product accumulation, activation of the renin–angiotensin system, low-grade inflammation and dysregulated lipid metabolism. Contemporary research has shifted towards a multiparametric biomarker approach, integrating glomerular markers (albumin, transferrin), tubular markers (N-acetyl-β-D-glucosaminidase, neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C), genetic polymorphisms affecting angiotensin-converting enzyme activity and emerging metabolic indicators such as pyruvate kinase M2. A comprehensive biomarker panel offers refined early detection, risk stratification and monitoring of therapeutic efficacy, complementing advances in targeted interventions like sodium–glucose cotransporter-2 inhibitors.

Research from Nature Portfolio

Recent studies have identified serum cystatin C and urinary haem oxygenase-1 as sensitive indicators of early tubular injury in people with type 2 diabetes. When assessed alongside angiotensin-converting enzyme insertion/deletion and G2350A genotypes, these markers correlated with subclinical changes in renal function before overt albuminuria. An earlier investigation, adopting a broad biomarker screen across 22 candidates, demonstrated that urinary transferrin, retinol-binding protein and serum osteopontin provided superior diagnostic accuracy for normoalbuminuric, microalbuminuric and macroalbuminuric stages respectively. This work highlighted that structural damage often precedes albumin excretion and underscored the value of combining glomerular and tubular markers for early diagnosis and staging.

Diabetic Nephropathy Biomarkers and Mechanisms publication trend

The graph below shows the total number of articles in diabetic nephropathy biomarkers and mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Albuminuria: Elevated albumin concentration in urine indicating glomerular permeability.

Biomarker: A measurable biological substance used to indicate normal or pathogenic processes.

Glomerular filtration barrier: The tri-layered structure in the kidney that filters blood plasma.

Microalbuminuria: The excretion of small amounts of albumin (30–300 mg per day), an early sign of nephropathy.

Proximal tubule epithelial cell: Renal cell type responsible for reabsorption and secretion in the nephron.

Renin–angiotensin system: Hormonal cascade regulating blood pressure and fluid balance, implicated in renal injury.

References

1. Urine biomarkers in type 2 diabetes mellitus with or without microvascular complications. Nutrition & Diabetes (2024).
2. Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy. International Journal of Molecular Sciences (2023).
3. Revisiting the Role of NAG across the Continuum of Kidney Disease. Bioengineering (2023).
4. Diagnostic efficacy of cystatin-c in association with different ACE genes predicting renal insufficiency in T2DM. Scientific Reports (2023).
5. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetology & Metabolic Syndrome (2019).
6. Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy. Journal of Diabetes Research (2016).
7. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators of Inflammation (2018).
8. Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients. Scientific Reports (2017).